IV iron safe, effective for paediatric IBD

  • Sabe R & al.
  • Glob Pediatr Health
  • 1 Jan 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Iron-deficiency anemia in paediatric patients with inflammatory bowel disease (IBD) can be safely and effectively treated with intravenous iron sucrose (IVIS).

Why this matters

  • IVIS is safe and effective for treating adults but is not well studied in children.

Study design

  • Researchers analysed the health records of patients aged
  • They defined efficacy as ≥2 g/dL increase in Hb ≤12 weeks from IVIS initiation.
  • Funding: None.

Key results

  • Adverse events occurred in 6 patients; none developed anaphylaxis.
  • Efficacy evaluations included 80 IVIS courses and showed that 58.7% (47) of courses resulted in goal haemoglobin (Hgb) increases.
  • Mean Hb rise was 9.1±1.4 to 11.9±1.8 g/dL (P<.0001 paired t-test>

Limitations

  • The study was retrospective and exploratory.
  • Some efficacy and minor adverse event data were missing or incomplete.